Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases

Journal of Steroid Biochemistry and Molecular Biology

Volumn 137, Issue , 2013, Pages 199-222

  Salvador, Jorge A R ^a,b   Pinto, Rui M A ^c   Silvestre, Samuel M ^d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c University School Vasco da Gama   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

17 Hydroxylase 17,20 lyase (CYP17); 5 Reductase; Prostate; Steroids

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; ABIRATERONE; ABIRATERONE ACETATE; ALFUZOSIN; BEXLOSTERIDE; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; EPRISTERIDE; EVEROLIMUS; FINASTERIDE; GALETERONE; GANODERIC ACID; GEFITINIB; HYDROCORTISONE; KETOCONAZOLE; LYASE INHIBITOR; MESTANOLONE; ORTERONEL; PLACEBO; PRASTERONE; PREDNISONE; PREGNENOLONE; SIPULEUCEL T; STANOZOLOL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN SYNTHESIS; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COVALENT BOND; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ENZYME SYNTHESIS; GROWTH INHIBITION; HUMAN; IC 50; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 84886716946     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.04.006     Document Type: Review

References (200)

1. A.C. Guyton, and J.E. Hall Textbook of Medical Physiology 10th ed. 2000 WB Saunders Company Philadelphia
2. W. Gao, C.E. Bohl, and J.T. Dalton Chemistry and structural biology of androgen receptor Chemical Reviews 105 2005 3352 3370 (Pubitemid 41430813)
3. L.J. Denis, and K. Griffiths Endocrine treatment in prostate cancer Seminars in Surgical Oncology 18 2000 52 74 (Pubitemid 30036120)
4. 17α and 5α-steroid reductase Natural Products Reports 15 1998 495 512 (Pubitemid 28514543)
5. B. Kenny, S. Ballard, J. Blagg, and D. Fox Pharmacological options in the treatment of benign prostatic hyperplasia Journal of Medicinal Chemistry 40 1997 1293 1315 and references cited therein (Pubitemid 27198078)
6. L.J. Schmidt, and D.J. Tindall Steroid 5α-reductase inhibitors targeting BPH and prostate cancer The Journal of Steroid Biochemistry and Molecular Biology 125 2011 32 38
7. S.V. Frye Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor Current Topics in Medicinal Chemistry 6 2006 405 421
8. K. Kulig, and B. Malawska Trends in the development of new drugs for treatment of benign prostatic hyperplasia Current Medicinal Chemistry 13 2006 3395 3416 (Pubitemid 44873752)
9. S. Aggarwal, S. Thareja, A. Verma, T.R. Bhardwaj, and M. Kumar An overview on 5α-reductase inhibitors Steroids 75 2010 109 153 and references cited therein
10. S.A. Cohen, and J.K. Parsons Combination pharmacological therapies for the management of benign prostatic hyperplasia Drugs and Aging 29 2012 275 284
11. J. Sun, H. Xiang, L.L. Yang, and J.B. Chen A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia Current Medicinal Chemistry 18 2011 3576 3589 and references cited therein
12. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA: A Cancer Journal for Clinicians 62 2012 10 29
13. P. Koivisto, M. Kolmer, T. Visakorpi, and O.P. Kallioniemi Androgen receptor gene and hormonal therapy failure of prostate cancer American Journal of Pathology 152 1998 1 9 (Pubitemid 28028039)
14. J.T. Isaacs, and W.B. Isaacs Androgen receptor outwits prostate cancer drugs Nature Medicine 10 2004 26 27 (Pubitemid 38524693)
15. B. Chatterjee The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer Molecular and Cellular Biochemistry 253 2003 89 101 (Pubitemid 37321715)
16. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Research 1 1941 293 297
17. C. Huggins, R.E. Stevens, and C.V. Hodges Studies on prostatic cancer. II. The effect of castration on clinical patients with carcinoma of the prostate Archives of Surgery 43 1941 209 223
18. V.M. Moreira, J.A.R. Salvador, T.S. Vasaitis, and V.C. Njar CYP17 inhibitors for prostate cancer treatment - an update Current Medicinal Chemistry 15 2008 868 899 and references cited therein (Pubitemid 351736409)
19. R. Dreicer, D.F. Bajorin, D.G. McLeod, D.P. Petrylak, and J.W. Moul New data, new paradigms for treating prostate cancer patients-VI: Novel hormonal therapy approaches Urology 78 2011 S494 S498 and references cited therein
20. K.N. Chi, A. Bjartell, D. Dearnaley, F. Saad, F.H. Schröder, C.B.T. Sternberg, and T. Visakorpi Castration-resistant prostate cancer: from new pathophysiology to new treatment targets European Urology 56 2009 594 605
21. M. Shelley, C. Harrison, B. Coles, J. Stafforth, T. Wilt, and M. Mason Chemotherapy for hormone-refractory prostate cancer Cochrane Database of Systematic Reviews 2006 4
22. J.R. Walczak, and M.A. Carducci Prostate cancer: a practical approach to current management of recurrent disease Mayo Clinic Proceedings 82 2007 243 249 (Pubitemid 46198485)
23. J.E. Ang, D. Olmos, and J.S. Bono CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer British Journal of Cancer 100 2009 671 675
24. G. Attard, C.S. Cooper, and J.S. de Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 2009 458 462
25. G. Attard, A.H.M. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Research 69 2009 4937 4940
26. J.B. Aragon-Ching, and W.L. Dahut Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer Drug Discovery Today: Therapeutic Strategies 7 2010 31 35
27. G. Attard, A.H.M. Reid, R. A'Hern, C. Parker, N.B. Oommen, E. Folkerd, C. Messiou, L.R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. Lee, M. Dowsett, S.B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J.S. de Bono Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer Journal of Clinical Oncology 27 2009 3742 3748
28. X. Li, C.L. Chen, S.M. Singh, and F. Labrie The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase Steroids 60 1995 430 441
29. J. Li, Z. Ding, Z. Wang, J.-F. Lu, S.N. Maity, N.M. Navone, C.J. Logothetis, G.B. Mills, and J. Kim Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention PLoS One 6 2011 e28840
30. M. Uemura, K. Tamura, S. Chung, S. Honma, A. Okuyama, Y. Nakamura, and H. Nakagawa Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer Cancer Science 99 2008 81 86 (Pubitemid 350239034)
31. F. Azzouni, A. Godoy, Y. Li, and J. Mohler The 5α-reductase isozyme family: a review of basic biology and their role in human diseases Advances in Urology 2012 10.1155/2012/530121
32. A. Godoy, E. Kawinski, Y. Li, D. Oka, B. Alexiev, F. Azzouni, M.A. Titus, and J.L. Mohler 5α-Reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression Prostate 71 2011 1033 1046
33. S. Aggarwal, S. Thareja, T.R. Bhardwaj, and M. Kumar Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5α-reductase inhibitors Steroids 75 2010 411 418
34. S. Aggarwal, S. Thareja, T.R. Bhardwaj, and M. Kumar 3D-QSAR studies on unsaturated 4-azasteroids as human 5α-reductase inhibitors: a self organizing molecular field analysis approach European Journal of Medicinal Chemistry 45 2010 476 481
35. S. Aggarwal, S. Thareja, A. Verma, T.R. Bhardwaj, and M. Kumar QSAR studies on human 5α-reductase inhibitors: unsaturated 3-carboxysteroids Acta Poloniae Pharmaceutica 2011 447 452
36. S. Thareja, S. Aggarwal, T.R. Bhardwaj, and M. Kumar Self organizing molecular field analysis on a series of human 5α-reductase inhibitors: Unsaturated 3-carboxysteroid European Journal of Medicinal Chemistry 44 2009 4920 4925
37. C.D. Jones, J.E. Audia, D.E. Lawhorn, L.A. McQuaid, B.L. Neubauer, A.J. Pike, P.A. Pennington, N.B. Stamm, R.E. Toomey, and K.S. Hirsch Nonsteroidal inhibitors of human type-I steroid 5α-reductase Journal of Medicinal Chemistry 36 1993 421 423 (Pubitemid 23067552)
38. J. Liu, K. Kurashiki, K. Shimizu, and R. Kondo Structure-activity relationship for inhibition of 5α-reductase by triterpenoids isolated from Ganoderma lucidum Bioorganic & Medicinal Chemistry 14 2006 8654 8660 (Pubitemid 44667519)
39. J. Liu, K. Kurashiki, K. Shimizu, and R. Kondo 5α-Reductase inhibitory effect of triterpenoids isolated from Ganoderma lucidum Biological & Pharmaceutical Bulletin 29 2006 392 395 (Pubitemid 43200919)
40. H.G. Bull, M. GarciaCalvo, S. Andersson, W.F. Baginsky, H.K. Chan, D.E. Ellsworth, R.R. Miller, R.A. Stearns, R.K. Bakshi, G.H. Rasmusson, R.L. Tolman, R.W. Myers, J.W. Kozarich, and G.S. Harris Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor Journal of the American Chemical Society 118 1996 2359 2365
41. D. Vaughan, J. Imperato-Mcginley, J. McConnell, A.M. Matsumoto, B. Bracken, J. Roy, M. Sullivan, F. Pappas, T. Cook, C. Daurio, A. Meehan, E. Stoner, and J. Waldstreicher Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia Urology 60 2002 1040 1044 (Pubitemid 35447563)
42. R.K. Bakshi, G.H. Rasmusson, G.F. Patel, R.T. Mosley, B. Chang, K. Ellsworth, G.S. Harris, and R.L. Tolman 4-Aza-3-oxo-5α-androst-1-ene- 17β-N-aryl-carboxamides as dual inhibitors of human type-1 and type-2 steroid 5α-reductases. Dramatic effect of N-aryl substituents on type-1 and type-2 5α-reductase inhibitory potency Journal of Medicinal Chemistry 38 1995 3189 3192
43. R.K. Bakshi, G.F. Patel, G.H. Rasmusson, W.F. Baginsky, G. Cimis, K. Ellsworth, B. Chang, H. Bull, R.L. Tolman, and G.S. Harris 4,7-β-Dimethyl- 4-azacholestan-3-one (Mk-386) and related 4-azasteroids as selective inhibitors of human type-1 5α-reductase Journal of Medicinal Chemistry 37 1994 3871 3874 (Pubitemid 24379673)
44. S.J. Keam, and L.J. Scott Dutasteride - a review of its use in the management of prostate disorders Drugs 68 2008 463 485 (Pubitemid 351342018)
45. E. di Salle, D. Giudici, A. Radice, T. Zaccheo, G. Ornati, M. Nesi, A. Panzeri, S. Delos, and P.M. Martin PNU 157706, a novel dual type I and II 5α-reductase inhibitor The Journal of Steroid Biochemistry and Molecular Biology 64 1998 179 186 (Pubitemid 28200990)
46. S. Kim, Y.-u. Kim, and E. Ma Synthesis and 5α-reductase inhibitory activity of C-21 steroids having 1,4-diene or 4,6-diene 20-ones and 4-azasteroid 20-oximes Molecules 17 2012 355 368
47. S. Kim, and E. Ma Synthesis of pregnane derivatives, their cytotoxicity on LNCap and PC-3 cells, and screening on 5α-reductase inhibitory activity Molecules 14 2009 4655 4668
48. E. Bellavance, V. Luu-The, and D. Poirier Potent and selective steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone Journal of Medicinal Chemistry 52 2009 7488 7502 and references cited therein
49. Z. Shuang, W. Jiazhen, Y. Lijuan, L. Zhuo, Y. Dahai, L. Jinfeng, Y. Jing, L. Yongtao, W. En-Si, and F. Xuexun Synthesis and bioactivity of new Finasteride conjugate Bioorganic & Medicinal Chemistry Letters 21 2011 3439 3442
50. 5-steroid isomerase by 6-azaandrost-4-en-3-ones. Optimization of the C17 substituent Journal of Medicinal Chemistry 38 1995 2621 2627
51. 5-steroid isomerase Journal of Medicinal Chemistry 37 1994 2352 2360
52. C. Haffner Synthesis of 6-azacholesten-3-ones - potent inhibitors of 5α-reductase Tetrahedron Letters 36 1995 4039 4042
53. A. Guarna, C. Belle, F. Machetti, E.G. Occhiato, A.H. Payne, C. Cassiani, A. Comerci, G. Danza, A. DeBellis, S. Dini, A. Marrucci, and M. Serio 19-nor-10-Azasteroids: a novel class of inhibitors for human steroid 5α-reductases 1 and 2 Journal of Medicinal Chemistry 40 1997 1112 1129 (Pubitemid 27149265)
54. D. Scarpi, E.G. Occhiato, G. Danza, M. Serio, and A. Guarna Synthesis of 17β-N-substituted 19-nor-10-azasteroids as inhibitors of human 5α-reductases I and II Bioorganic & Medicinal Chemistry 10 2002 3455 3461
55. D.S. Yamashita, D.A. Holt, H.J. Oh, D. Shah, H.K. Yen, M. Brandt, and M.A. Levy 3-Carboxy-20-keto steroids are dual uncompetitive inhibitors of human steroid 5α-reductase types 1 and 2 Bioorganic & Medicinal Chemistry 4 1996 1481 1485 (Pubitemid 26319998)
56. 3,5(6)-steroids as new potential 5α-reductase inhibitor Bioorganic & Medicinal Chemistry Letters 8 1998 1949 1952 (Pubitemid 28372468)
57. Z. Yao, Y. Xu, M. Zhang, S. Jiang, M.C. Nicklaus, and C. Liao Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor Bioorganic & Medicinal Chemistry Letters 21 2011 475 478
58. S. Aggarwal, S. Thareja, T.R. Bhardwaj, J. Haupenthal, R.W. Hartmann, and M. Kumar Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach European Journal of Medicinal Chemistry 54 2012 728 739
59. D.A. Holt, M.A. Levy, H.J. Oh, J.M. Erb, J.I. Heaslip, M. Brandt, H.Y. Lanhargest, and B.W. Metcalf Inhibition of steroid 5α-reductase by unsaturated 3-carboxysteroids Journal of Medicinal Chemistry 33 1990 943 950 (Pubitemid 20085897)
60. D.A. Holt, M.A. Levy, D.L. Ladd, H.J. Oh, J.M. Erb, J.I. Heaslip, M. Brandt, and B.W. Metcalf Steroidal a-ring aryl carboxylic-acids - a new class of steroid 5α-reductase inhibitors Journal of Medicinal Chemistry 33 1990 937 942 (Pubitemid 20085896)
61. D.A. Holt, M.A. Levy, H.K. Yen, H.J. Oh, B.W. Metcalf, and P.J. Wier Inhibition of steroid 5α-reductase by 3-nitrosteroids - synthesis, mechanism of inhibition, and in vivo activity Bioorganic & Medicinal Chemistry Letters 1 1991 27 32
62. D.A. Holt, H.J. Oh, M.A. Levy, and B.W. Metcalf Synthesis of a steroidal a-ring aromatic sulfonic-acid as an inhibitor of steroid 5α-reductase Steroids 56 1991 4 7
63. M.A. Levy, B.W. Metcalf, M. Brandt, J.M. Erb, H.J. Oh, J.I. Heaslip, H.K. Yen, L.W. Rozamus, and D.A. Holt 3-Phosphinic acid and 3-phosphonic acid steroids as inhibitors of steroid 5α-reductase - species comparison and mechanistic studies Bioorganic Chemistry 19 1991 245 260
64. E. Bratoeff, M. Cabeza, E. Ramirez, Y. Heuze, and E. Flores Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5α-reductase inhibitors Current Medicinal Chemistry 12 2005 927 943 (Pubitemid 40443848)
65. E. Flores, E. Bratoeff, M. Cabeza, E. Ramirez, A. Quiroz, and I. Heuze Steroid 5α-reductase inhibitors Mini-Reviews in Medicinal Chemistry 3 2003 225 237
66. E. Bratoeff, T. Sainz, M. Cabeza, I. Heuze, S. Recillas, V. Perez, C. Rodriguez, T. Segura, J. Gonzales, and E. Ramirez Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5α-reductase The Journal of Steroid Biochemistry and Molecular Biology 107 2007 48 56 (Pubitemid 47362674)
67. E. Bratoeff, T. Segura, S. Recillas, E. Carrizales, A. Palacios, I. Heuze, and M. Cabeza Aromatic esters of progesterone as 5α-reductase and prostate growth inhibitors Journal of Enzyme Inhibition and Medicinal Chemistry 24 2009 655 662
68. E. Bratoeff, P. Garcia, Y. Heuze, J. Soriano, A. Mejia, A. Maria Labastida, N. Valencia, and M. Cabeza Molecular interactions of progesterone derivatives with 5α-reductase types 1 and 2 and androgen receptors Steroids 75 2010 499 505
69. M. Cabeza, E. Bratoeff, I. Heuze, A. Rojas, N. Terán, M. Ochoa, T. Ramírez-Apan, E. Ramírez, V. Pérez, and I. Gracia New progesterone derivatives as inhibitors of 5α-reductase enzyme and prostate cancer cell growth Journal of Enzyme Inhibition and Medicinal Chemistry 2006 371 378 (Pubitemid 44355785)
70. E. Ramirez, M. Cabeza, E. Bratoeff, I. Heuze, V. Perez, D. Valdez, M. Ochoa, N. Teran, G. Jimenez, and T. Ramirez Synthesis and pharmacological evaluation of new progesterone esters as 5α-reductase inhibitors Chemical& Pharmaceutical Bulletin 53 2005 1515 1518 (Pubitemid 41744474)
71. E. Bratoeff, A. Zambrano, I. Heuze, A. Palacios, D. Ramirez, and M. Cabeza Synthesis and biological activity of progesterone derivatives as 5α-reductase inhibitors, and their effect on hamster prostate weight Journal of Enzyme Inhibition and Medicinal Chemistry 25 2010 306 311
72. M. Cabeza, A. Zambrano, I. Heuze, E. Carrizales, A. Palacios, T. Segura, N. Valencia, and E. Bratoeff Novel C-6 substituted and unsubstituted pregnane derivatives as 5α-reductase inhibitors and their effect on hamster flank organs diameter size Steroids 74 2009 793 802
73. V. Perez-Ornelas, M. Cabeza, E. Bratoeff, I. Heuze, M. Sanchez, E. Ramirez, and E. Naranjo-Rodriguez New 5α-reductase inhibitors: in vitro and in vivo effects Steroids 70 2005 217 224 (Pubitemid 40342616)
74. E. Bratoeff, M. Cabeza, V. Perez-Ornelas, S. Recillas, and I. Heuze In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors The Journal of Steroid Biochemistry and Molecular Biology 111 2008 275 281
75. C.P. Owen 17α-Hydroxylase/17,20-lyase (P45017α) inhibitors in the treatment of prostate cancer: a review Anti-Cancer Agents in Medicinal Chemistry 9 2009 613 626
76. N. Dhingra, T.R. Bhardwaj, N. Mehta, T. Mukhopadhyay, A. Kumar, and M. Kumar Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams European Journal of Medicinal Chemistry 45 2010 2229 2236
77. N. Dhingra, T.R. Bhardwaj, N. Mehta, T. Mukhopadhyay, A. Kumar, and M. Kumar 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level Medicinal Chemistry Research 20 2011 817 825
78. N. Dhingra, T.R. Bhardwaj, N. Mehta, T. Mukhopadhyay, A. Kumar, and M. Kumar Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives Archives of Pharmacal Research 34 2011 1055 1063
79. Y. Arellano, E. Bratoeff, M. Garrido, J. Soriano, Y. Heuze, and M. Cabeza New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors Steroids 76 2011 1241 1246
80. M. Garrido, E. Bratoeff, D. Bonilla, J. Soriano, Y. Heuze, and M. Cabeza New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor The Journal of Steroid Biochemistry and Molecular Biology 127 2011 367 373
81. J. Wölfling, L. Hackler, E. Mernyák, G. Schneider, I. Tóth, M. Szécsi, J. Julesz, P. Sohár, and A. Csámpai Neighboring group participation - Part 15. Stereoselective synthesis of some steroidal tetrahydrooxazin-2-ones, as novel presumed inhibitors of human 5α-reductase Steroids 69 2004 451 460 (Pubitemid 38891798)
82. M. Szécsi, D. Ondré, I. Tóth, S. Magony, J. Wölfling, G. Schneider, and J. Julesz Determination of rat 5α-reductase type I isozyme activity and its inhibition by novel steroidal oxazolines Acta Biologica Hungarica 61 2010 274 281
83. A.M. Al-Mohizea, M.A. Al-Omar, M.M. Abdalla, and A.-G.E. Amr 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives International Journal of Biological Macromolecules 50 2012 171 179
84. R.J. Hamilton, G.L. Andriole, and S.J. Freedland 5α-Reductase inhibitors: preventing the treatable European Urology 62 2012 242 244
85. J.M. Golbano, P. Lopez-Aparicio, M.N. Recio, and M.A. Perez-Albarsanz Finasteride induces apoptosis via Bcl-2, Bcl-x(L). Bax and caspase-3 proteins in LNCaP human prostate cancer cell line International Journal of Oncology 32 2008 919 924 (Pubitemid 351780602)
86. Y. Xu, S.L. Dalrymple, R.E. Becker, S.R. Denmeade, and J.T. Isaacs Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers Clinical Cancer Research 12 2006 4072 4079 (Pubitemid 44078095)
87. N.E. Fleshner, M.S. Lucia, B. Egerdie, L. Aaron, G. Eure, I. Nandy, L. Black, and R.S. Rittmaster Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet 379 2012 1103 1111
88. F. Schröder, C. Bangma, J.C. Angulo, A. Alcaraz, M. Colombel, T. McNicholas, T.L. Tammela, I. Nandy, and R. Castro Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised. placebo-controlled avodart after radical therapy for prostate cancer study (ARTS) European Urology 63 2012 779 787
89. M. Akhtar, J.N. Wright, and P. Lee-Robichaud A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17) The Journal of Steroid Biochemistry and Molecular Biology 125 2011 2 12
90. B.C. Chung, J. Picado-Leonard, M. Haniu, M. Bienkowski, P.F. Hall, J.E. Shively, and W.L. Miller Cytochrome P450c17 (Steroid 17α-Hydroxylase/17,20 Lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues Proceedings of the National Academy of Sciences United States of America 84 1987 407 411 (Pubitemid 17006204)
91. scc to 15q23-q24, adrenodoxin to 11q22, adrenodoxin reductase to 17q24-q25, and P450c17 to 10q24-q25 DNA and Cell Biology 10 1991 359 365
92. 17α) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding Genomics 14 1992 1110 1111 (Pubitemid 23053056)
93. 21 steroid side chain cleavage. Spectral and binding studies Journal of Biological Chemistry 256 1981 6134 6139
94. 17,20 lyase) Journal of Biological Chemistry 256 1981 3871 3876
95. 17,20-Lyase) associated with one protein Biochemistry 20 1981 4037 4042
96. M.X. Zuber, E.R. Simpson, and M.R. Waterman Expression of bovine 17α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells Science 234 1986 1258 1261 (Pubitemid 17232368)
97. 21 steroid side-chain cleavage cytochrome P-450 from neonatal porcine testis: a Unique Cysteine residue alkylated by 17-(bromoacetoxy)progesterone Biochemistry 26 1987 657 662 (Pubitemid 17022141)
98. 21scc: one enzyme with two actions: hydroxylase and lyase The Journal of Steroid Biochemistry and Molecular Biology 40 1991 527 532
99. K. Yanagibashi, and P.F. Hall Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage p-450 from porcine adrenal and testicular microsomes Journal of Biological Chemistry 261 1986 8429 8433 (Pubitemid 17202723)
100. D. Lin, S.M. Black, Y. Nagahama, and W.L. Miller Steroid 17α-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase Endocrinology 132 1993 2498 2506 (Pubitemid 23156900)
101. 5 and by serine phosphorylation of P450c17 Journal of Biological Chemistry 280 2005 13265 13271 (Pubitemid 40517210)
102. 5 in androgen-synthesizing tissues of the human Biology of Reproduction 71 2004 83 88 (Pubitemid 38915312)
103. 5 modulation of 17α-hydroxylase and 17,20-lyase (CYP17) activities in steroidogenesis Journal of Endocrinology 187 2005 267 274 (Pubitemid 41685186)
104. 5 requires residues E48 and E49 to stimulate the 17,20-lyase activity of cytochrome P450c17 Biochemistry 45 2006 755 762 (Pubitemid 43122240)
105. L.H. Zhang, H. Rodriguez, S. Ohno, and W.L. Miller Serine phosphorylation of human p450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome Proceedings of the National Academy of Sciences United States of America 92 1995 10619 10623
106. A.V. Pandey, S.H. Mellon, and W.L. Miller Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17 Journal of Biological Chemistry 278 2003 2837 2844 (Pubitemid 36801187)
107. I. Souter, I. Munir, P. Mallick, S.R. Weitsman, D.H. Geller, and D.A. Magoffin Mutagenesis of putative serine-threonine phosphorylation sites proximal to Arg255 of human cytochrome P450c17 does not selectively promote its 17,20-lyase activity Fertility and Sterility 85 2006 1290 1299
108. D.H. Geller, R.J. Auchus, B.B. Mendonca, W.L. Miller, and The Genetic Functional basis of isolated 17,20-lyase deficiency Nature Genetics 17 1997 201 205
109. 5 to promote male sex-hormone biosynthesis Biochemical Journal 342 1999 309 312 (Pubitemid 29425351)
110. E.L. Van Den Akker, J.W. Koper, A.L. Boehmer, A.P. Themmen, M. Verhoef-Post, M.A. Timmerman, B.J. Otten, S.L. Drop, and F.H. De Jong Differential inhibition of 17α-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency The Journal of Clinical Endocrinology and Metabolism 87 2002 5714 5721 (Pubitemid 36034381)
111. D.P. Sherbet, D. Tiosano, K.M. Kwist, Z. Hochberg, and R.J. Auchus CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding Journal of Biological Chemistry 278 2003 48563 48569 (Pubitemid 41079494)
112. S.M. Haider, J.S. Patel, C.S. Poojari, and S. Neidle Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy Journal of Biological Chemistry 400 2010 1078 1098
113. N.M. DeVore, and E.E. Scott Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 Nature 482 2012 116 120
114. A. Mancuso, S. Oudard, and C.N. Sternberg Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments Critical Reviews in Oncology/Hematology 61 2007 176 185 (Pubitemid 46091748)
115. A.L. Harzstark, and E.J. Small Castrate-resistant prostate cancer: therapeutic strategies Expert Opinion on Pharmacotherapy 11 2010 937 945
116. M. Nakabayashi, W. Xie, M.M. Regan, D.M. Jackman, P.W. Kantoff, and W.K. Oh Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer Cancer 107 2006 975 981 (Pubitemid 44291146)
117. J. Trachtenberg Ketoconazole therapy in advanced prostatic cancer Journal of Urology 132 1984 61 63 (Pubitemid 14087473)
118. F. Dayyani, G.E. Gallick, C.J. Logothetis, and P.G. Corn Novel therapies for metastatic castrate-resistant prostate cancer Journal of the National Cancer Institute 103 2011 1665 1675
119. A.D. Choudhury, and P.W. Kantoff New agents in metastatic prostate cancer Journal of the National Comprehensive Cancer Network 10 2012 1403 1409
120. O. Sartor Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space Journal of Hematology & Oncology 4 2011 18
121. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, K. Thian, C.M. Haqq, and H.I. Scher Abiraterone and increased survival in metastatic prostate cancer New England Journal of Medicine 364 2011 1995 2005
122. G. Sonpavde Abiraterone and increased survival in metastatic prostate cancer New England Journal of Medicine 365 2011 766 767
123. G. Sonpavde, G. Attard, J. Bellmunt, M.D. Mason, B. Malavaud, B. Tombal, and C.N. Sternberg The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature European Urology 60 2011 270 278
124. C.J. Logothetis, E. Efstathiou, F. Manuguid, and P. Kirkpatrick Abiraterone acetate Nature Reviews Drug Discovery 10 2011 573 574
125. A. Bryce, and C.J. Ryan Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor Clinical Pharmacology & Therapeutics 9 2012 101 108
126. H.I. Scher, K. Fizazi, F. Saad, M.-E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J.S. de Bono Increased survival with enzalutamide in prostate cancer after chemotherapy New England Journal of Medicine 367 2012 1187 1197
127. T.S. Vasaitis, and V.C.O. Njar Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments Future Medicinal Chemistry 2 2010 667 680
128. A. Molina, and A. Belldegrun Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling Journal of Urology 185 2011 787 794
129. T.S. Vasaitis, R.D. Bruno, and V.C.O. Njar CYP17 inhibitors for prostate cancer therapy The Journal of Steroid Biochemistry and Molecular Biology 125 2011 23 31
130. R. Larsson, N.P. Mongan, M. Johansson, L. Shcherbina, P.-A. Abrahamsson, L.J. Gudas, O. Sterner, and J.L. Persson Clinical trial update and novel therapeutic approaches for metastatic prostate cancer Current Medicinal Chemistry 18 2011 4440 4453
131. E. Baston, and F. Leroux Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets For Drug Development Recent Patents in Anti-Cancer Drug Discovery 2 2007 31 58 (Pubitemid 46729085)
132. R.W. Hartmann, P.B. Ehmer, S. Haidar, M. Hector, J. Jose, C.D. Klein, S.B. Seidel, T.F. Sergejew, B.G. Wachall, G.A. Wachter, and Y. Zhuang Inhibition of CYP 17, a new strategy for the treatment of prostate cancer Archiv der Pharmazie 335 2002 119 128 (Pubitemid 34728739)
133. M.R. Angelastro, T.R. Blohm, 4-Substituted 17b-(cyclopropyloxy)androst-5- en-3b-ol and related compounds useful as C17,20-lyase inhibitors, US Pat 4,966,897, 1990.
134. 17,20-lyase) Biochemical and Biophysical Research Communications 162 1989 1571 1577 (Pubitemid 19214763)
135. 17(20)-lyase by 17β-cyclopropyl ether-substituted steroids Bioorganic & Medicinal Chemistry Letters 6 1996 97 100
136. 17,20-lyase and 5α-reductase, US Patent 5,486,511, 1996.
137. 4-3-ketosteroids, WO Patent 95/29932, 1995.
138. J.P. Burkhart, P.M. Weintraub, C.A. Gates, R.J. Resvick, R.J. Vaz, D. Friedrich, M.R. Angelastro, P. Bey, and N.P. Peet Novel steroidal vinyl fluorides as inhibitors of steroid C-17(20) lyase Bioorganic & Medicinal Chemistry 10 2002 929 934 (Pubitemid 34139908)
139. 17(20)-lyase Bioorganic & Medicinal Chemistry 11 2003 427 431 (Pubitemid 36051033)
140. 17(20)-lyase Bioorganic & Medicinal Chemistry 10 2002 929 934 (Pubitemid 34139908)
141. S. R. Wilson, E. Miao, Anti-testosterone compounds and method of use thereof, WO Patent 92/15604, 1992.
142. N.P. Peet, P.M. Weintraub, J.P. Burkhart, C. Gates, 20-Fluoro-17(20)- vinyl steroids, US Patent 6,413,951 B2, 2002.
143. 17,20-lyase and 5α-reductase, WO Patent 02/00681 A1, 2002.
144. G.E. Arth, A.A. Patchett, T. Jefopoulus, R.L. Bugianesi, L.H. Peterson, E.A. Ham, F.A. Kuehl, and N.G. Brink Steroidal androgen biosynthesis inhibitors Journal of Medicinal Chemistry 14 1971 675 679
145. 17,20-lyase) Chemical & Pharmaceutical Bulletin 37 1989 1855 1858 (Pubitemid 19204992)
146. A. Brodie, L. Jisong, 20-Substituted pregnene derivatives and their use as androgen inhibitors, US Patent 5,264,427, 1993.
147. A. Brodie, L. Yangzhi, Androgen synthesis inhibitors, US Patent 6,133,280, 2000.
148. 20-lyase Journal of Medicinal Chemistry 39 1996 4335 4339 (Pubitemid 26339844)
149. 17,20-lyase and of 5α-reductase The Journal of Steroid Biochemistry and Molecular Biology 42 1992 313 320
150. Y. Ling, J. Li, K. Kato, Y. Liu, X. Wang, G.T. Klus, K. Marat, I.P. Nnane, and A.M.H. Brodie Synthesis and in vitro activity of some epimeric 20α-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17α-hydroxylase/C17,20-lyase and 5α-reductase Bioorganic & Medicinal Chemistry 6 1998 1683 1693 (Pubitemid 28524224)
151. 17,20-Lyase) and 5α-reductase types 1 and 2 Journal of Medicinal Chemistry 43 2000 4266 4277
152. 17,20-lyase) Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry 334 2001 138 140 (Pubitemid 32385629)
153. 17,20-lyase (P450 17) Bioorganic & Medicinal Chemistry 4 1996 1447 1453 (Pubitemid 26319995)
154. 17,20-lyase (P450 17) Journal of Medicinal Chemistry 43 2000 4437 4445 (Pubitemid 32046868)
155. J.J. Deadman, R. McCague, and M. Jarman Heptafluoro-p-tolyl as a protecting group in a synthesis of 3-hydroxy-17a-aza-17a-homopregn-5-en-20-one. A potential inhibitor of androgen biosynthesis Journal of Chemical Society Perkin 1 1991 2413 2416
156. T.T. Curran, G.A. Flynn, D.E. Rudisill, and P.M. Weintraub A novel route to a 4-amino steroid - MDL 19687 Tetrahedron Letters 36 1995 4761 4764
157. J. Li, Y. Li, C. Son, and A.M. Brodie Inhibition of androgen synthesis by 22-hydroximino-23,24-Bisnor-4-cholen-3-one Prostate 26 1995 140 150
158. 17,20-Lyase): potential agents for the treatment of prostatic cancer Journal of Medicinal Chemistry 38 1995 2463 2471
159. 17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo The Journal of Steroid Biochemistry and Molecular Biology 84 2003 555 562 (Pubitemid 36588809)
160. 17α by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3β-ol) and related steroidal inhibitors Journal of Medicinal Chemistry 41 1998 5375 5381 (Pubitemid 29031321)
161. 17α (17α-hydroxylase C17-20 lyase) The Journal of Steroid Biochemistry and Molecular Biology 50 1994 267 273 (Pubitemid 24309119)
162. A. O'Donnell, I. Judson, M. Dowset, F. Raynaud, D. Dearnaley, M. Mason, S. Harland, A. Robbins, G. Halbert, B. Nutley, and M. Jarman Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer British Journal of Cancer 90 2004 2317 2325 (Pubitemid 38961894)
163. A. Eichholz, R. Ferraldeschi, G. Attard, and J.S. de Bono Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer Molecular and Cellular Endocrinology 360 2012 68 75
164. G. Attard, A.H. Reid, T.A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, J. Clark, C.S. Cooper, S.B. Kaye, D. Dearnaley, G. Lee, and J.S. de Bono Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven Journal of Clinical Oncology 26 2008 4563 4571
165. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, F. Raynaud, V. Martins, G. Lee, T. Kheoh, J. Kim, A. Molina, and E.J. Small Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy Journal of Clinical Oncology 28 2010 1481 1488
166. D.C. Danila, M.J. Morris, J.S. de Bono, C.J. Ryan, S.R. Denmeade, M.R. Smith, M.E. Taplin, G.J. Bubley, T. Kheoh, C. Haqq, A. Molina, A. Anand, M. Koscuiszka, S.M. Larson, L.H. Schwartz, M. Fleisher, and H.I. Scher Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer Journal of Clinical Oncology 28 2010 1496 1501
167. A.H. Reid, G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, L.R. Molife, J. Hunt, C. Messiou, C. Parker, D. Dearnaley, J.F. Swennenhuis, L.W. Terstappen, G. Lee, T. Kheoh, A. Molina, C.J. Ryan, E. Small, H.I. Scher, and J.S. de Bono Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate Journal of Clinical Oncology 28 2010 1489 1495
168. S.E. Barrie, M. Jarman, G.A. Potter, I.R. Hardcastle, 17-Substituted steroids useful in cancer treatment, US Patent 5,604, 213, 1997.
169. 17,20-lyase) Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry 334 2001 373 374 (Pubitemid 34118728)
170. 17α) Journal of Medicinal Chemistry 40 1997 3297 3304 (Pubitemid 27413755)
171. D. Ondré, J. Wölfling, Z. Iványi, G. Schneider, I. Tóth, M. Szécsi, and J. Julesz Neighboring group participation. Part 17 Stereoselective synthesis of some steroidal 2-oxazolidones, as novel potential inhibitors of 17α-hydroxylase-C17,20-lyase Steroids 73 2008 1375 1384
172. D. Ondré, J. Wölfling, I. Tóth, M. Szécsi, J. Julesz, and G. Schneider Steroselective synthesis of some steroidal oxazolines, as novel potential inhibitors of 17α-hydroxylase-C17,20-lyase Steroids 74 2009 1025 1032
173. Z. Iványi, J. Wölfling, T. Görbe, M. Szécsi, T. Wittmann, and G. Schneider Synthesis of regioisomeric 17-N-phenylpyrazolyl steroid derivatives and their inhibitory effect on 17α-hydroxylase/C17,20- lyase Steroids 75 2010 450 456
174. E. Frank, Z. Mucsi, M. Szecsi, I. Zupko, J. Wolfling, and G. Schneider Intramolecular approach to some new D-ring-fused steroidal isoxazolidines by 1,3-dipolar cycloaddition: synthesis, theoretical and in vitro pharmacological studies New Journal of Chemistry 34 2010 2671 2681
175. 17(20)-lyase with C17-heteroaryl steroids Bioorganic & Medicinal Chemistry 4 1996 1411 1420 (Pubitemid 26319992)
176. 17,20-lyase inhibitors, US Patent 5,977,094, 1999.
177. 17,20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer Cancer Research 58 1998 3826 3832 (Pubitemid 28405637)
178. G.T. Klus, J. Nakamura, J.S. Li, Y.Z. Ling, C. Son, J.A. Kemppainen, E.M. Wilson, and A.M. Brodie Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis Cancer Research 56 1996 4956 4964 (Pubitemid 26374435)
179. B.J. Long, D.N. Grigoryev, I.P. Nnane, Y. Liu, Y.Z. Ling, and A.M. Brodie Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer Cancer Research 60 2000 6630 6640
180. I.P. Nnane, B.J. Long, Y.Z. Ling, D.N. Grigoryev, and A.M. Brodie Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4, 16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis British Journal of Cancer 83 2000 74 82 (Pubitemid 30352720)
181. I.P. Nnane, V.C.O. Njar, and A.M.H. Brodie Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice Cancer Chemotherapy and Pharmacology 51 2003 519 524 (Pubitemid 36791679)
182. 17,20-lyase Steroids 71 2006 809 816 (Pubitemid 44062604)
183. 16-steroids, inhibitors of 17α-hydroxylase/17,20-lyase (17α-lyase) Bioorganic & Medicinal Chemistry Letters 6 1996 2777 2782 (Pubitemid 26387265)
184. 17α): potential agents for the treatment of prostate cancer Journal of Medicinal Chemistry 41 1998 902 912
185. A. Brodie, V.C. Njar, 17-Azolyl steroids useful as androgen synthesis inhibitors, US Patent 6,200,965 B1, 2001.
186. V.D. Handratta, D. Jelovac, B.J. Long, R. Kataria, I.P. Nnane, V.C. Njar, and A.M. Brodie Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model The Journal of Steroid Biochemistry and Molecular Biology 92 2004 155 165 (Pubitemid 39539227)
187. 17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo British Journal of Cancer 81 1999 622 630 (Pubitemid 29458857)
188. I.P. Nnane, V.C. Njar, Y. Liu, Q. Lu, and A.M. Brodie Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo The Journal of Steroid Biochemistry and Molecular Biology 71 1999 145 152 (Pubitemid 30001813)
189. V.D. Handratta, T.S. Vasaitis, V.C. Njar, L.K. Gediya, R. Kataria, P. Chopra, D. Newman, R. Farquhar, Z. Guo, Y. Qiu, and A.M. Brodie Novel C17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model Journal of Medicinal Chemistry 48 2005 2972 2984 (Pubitemid 40552912)
190. A. Brodie, V.C. Njar, Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity, WO Patent 2006/093993, 2006.
191. T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L.K. Gediya, Z. Guo, H.B. Fang, V.C.O. Njar, and A.M.H. Brodie Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20- lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Molecular Cancer Therapeutics 7 2008 2348 2357
192. A. Schayowitz, G. Sabnis, V.C.O. Njar, and A.M.H. Brodie Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Molecular Cancer Therapeutics 7 2008 121 132
193. A. Schayowitz, G. Sabnis, O. Goloubeva, V.C.O. Njar, and A.M.H. Brodie Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR British Journal of Cancer 103 2010 1001 1007
194. H.S. Soifer, N. Souleimanian, S. Wu, A.M. Voskresenskiy, F.K. Collak, B. Cinar, and C.A. Stein Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells Journal of Biological Chemistry 287 2012 3777 3787
195. http://clinicaltrials.gov/show/NCT00959959: ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (accessed 2 December 2012).
196. M.-E. Taplin, F. Chu, J.P. Morrison, R. Pili, M.B. Rettig, J. Stephenson, N.J. Vogelzang, and R.B. Montgomery ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC) Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012 Mar 31-Apr 4, vol. 72, no. 8 Suppl. Chicago, IL 2012 AACR. Cancer Research Philadelphia (PA) (Abstract CT-07)
197. R.D. Bruno, T.S. Vasaitis, L.K. Gediya, P. Purushottamachar, A.M. Godbole, Z. Ates-Alagoz, A.M.H. Brodie, and V.C.O. Njar Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model Steroids 76 2011 1268 1279
198. V.M. Moreira, T.S. Vasaitis, V.C. Njar, and J.A.R. Salvador Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors Steroids 72 2007 939 948 (Pubitemid 47600277)
199. V.M. Moreira, J.A.R. Salvador, A.M. Beja, J.A. Paixao, T.S. Vasaitis, and V.C.O. Njar C16 and C17-heterocycle bearing androstanes. CYP17 inhibition studies and multiple effects on prostate cancer cells European Journal of Pharmaceutical Sciences 44 2011 43 44
200. V.M.A. Moreira, T.S. Vasaitis, Z. Guo, V.C.O. Njar, and J.A.R. Salvador Synthesis of novel C17 steroidal carbamates Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth Steroids 73 2008 1217 1227